Skip to main content

Advertisement

SpringerLink
Log in

Lobular Neoplasia

  • Non-Invasive Breast Cancer Diagnosis and Treatment (ES Hwang, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Today, the term lobular neoplasia (LN) incorporates atypical lobular hyperplasia (ALH), classical lobular carcinoma in situ (C-LCIS) and nonclassical lobular carcinoma in situ (NC-LCIS). These neoplastic lesions are thought of as risk indicators and non-obligate precursors of invasive breast cancer. This review highlights the current literature and up-to-date treatment recommendations for ALH, C-LCIS, and NC-LCIS.

Recent Findings

Currently, NC-LCIS requires surgical excision to rule out a concurrent carcinoma; but a core biopsy diagnosis of ALH or C-LCIS can be safely managed with close clinical and imaging observation, elevated future breast cancer risk counseling and consideration for chemoprevention. Controversy regarding categorizing NC-LCIS remains with respect to its histologic features and terminology.

Summary

The treatment and surveillance recommendations for LN continue to evolve. Overall, the treatment of LN requires a multidisciplinary approach to ensure appropriate screening and comprehensive counseling about the elevated lifetime breast cancer risk and about standard and investigational breast cancer risk-reducing options in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ewing J. Neoplastic diseases, a text-book on tumors. Pennsylvania: W. B. Saunders company; 1919.

    Google Scholar 

  2. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–496.3.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.

    Article  CAS  PubMed  Google Scholar 

  4. Bentz JS, Yassa N, Clayton F. Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol. 1998;11(9):814–22.

    CAS  PubMed  Google Scholar 

  5. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol. 2000;24(12):1650–6. https://doi.org/10.1097/00000478-200012000-00009.

    Article  CAS  PubMed  Google Scholar 

  6. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol. 2002;15(10):1044–50. https://doi.org/10.1097/01.MP.0000027624.08159.19.

    Article  PubMed  Google Scholar 

  7. Page DL, TEK J, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.

    Article  CAS  PubMed  Google Scholar 

  8. Abdel-Fatah T, Powe DG, Hodi Z, Lee AHS, Reis-Filho J, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;3:417.

    Article  Google Scholar 

  9. Frost AR, Tsangaris TNSS. Pleomorphic lobular carcinoma in situ. Pathol Case Rev. 1996;1:27–31.

    Article  Google Scholar 

  10. Dabbs DJ, Schnitt SJ, Geyer FC, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–e11. https://doi.org/10.1097/PAS.0b013e3182918a2b.

    Article  PubMed  Google Scholar 

  11. Canas-Marques R, Schnitt SJ. E-cadherin immunohistochemistry in breast pathology: uses and pitfalls. Histopathology. 2016;68(1):57–69. https://doi.org/10.1111/his.12869.

    Article  PubMed  Google Scholar 

  12. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001;3(5):289–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Andrade VP, Morrogh M, Qin L-X, Olvera N, Giri D, Muhsen S, et al. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol. 2015;9(4):772–82. https://doi.org/10.1016/j.molonc.2014.12.005.

    Article  CAS  PubMed  Google Scholar 

  14. Shin SJ, Lal A, De Vries S, et al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol. 2013;44(10):1998–2009. https://doi.org/10.1016/j.humpath.2013.04.004.

    Article  CAS  PubMed  Google Scholar 

  15. Chen Y-Y, Hwang E-SS, Vincent-Salomon A, et al. Genetic and Phenotypic Characteristics of Pleomorphic Lobular Carcinoma In Situ of the Breast. Am J Surg Pathol. 2009;11:1683.

    Article  Google Scholar 

  16. • Petridis C, Arora I, Shah V, et al. Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer. Cancer Epidemiol Biomark Prev. 2019;28(7):1162–8 Excess of pathogenic variants in BRCA2, CHEK2, PALB2, and CDH1 in women with ILC. CHEK2 was the only gene that showed an association with pure LCIS. Women with ILC ages ≤40 years should be offered genetic screening using a panel of genes that includes BRCA2, CHEK2, PALB2, and CDH.

    Article  Google Scholar 

  17. Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. Cancer Epidemiol Biomark Prev. 2009;18(6):1763–9. https://doi.org/10.1158/1055-9965.EPI-08-1082.

    Article  Google Scholar 

  18. Beute BJ, Kalisher L, Hutter RVP. Lobular carcinoma in situ of the breast : clinical, pathologic, and mammographic features. Am J Roentgenol. 1991;2:257.

    Article  Google Scholar 

  19. Scoggins M, Krishnamurthy S, Santiago L, Yang W. Lobular carcinoma in situ of the breast: clinical, radiological, and pathological correlation. Acad Radiol. 2013;20(4):463–70. https://doi.org/10.1016/j.acra.2012.08.020.

    Article  PubMed  Google Scholar 

  20. • Maxwell AJ, Clements K, Dodwell DJ, et al. The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project. Breast. 2016;27:109–15. https://doi.org/10.1016/j.breast.2016.03.004Screen-detected LN commonly occurs in women age 50–54. It is predominantly non-pleomorphic and unilateral. It is typically associated with granular or punctate microcalcification. Management, including surgical resection, is highly variable.

    Article  PubMed  Google Scholar 

  21. • Amos B, Chetlen A, Williams N. Atypical lobular hyperplasia and lobular carcinoma in situ at core needle biopsy of the breast: an incidental finding or are there characteristic imaging findings? Breast Dis. 2016;36(1):5–14. https://doi.org/10.3233/BD-150194Mammographically detected calcifications and foci or non-mass enhancement on magnetic resonance imaging can be considered concordant imaging findings of lobular neoplasia after breast core-needle biopsy.

    Article  PubMed  Google Scholar 

  22. Rosen PP, Brogi E, Hoda SA, Koerner FC. Rosen’s Breast Pathology. Fourth. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.

    Google Scholar 

  23. Helvie MA, Hessler C, Frank TS, Ikeda DM. Atypical hyperplasia of the breast: mammographic appearance and histologic correlation. Radiology. 1991;179(3):759–64.

    Article  CAS  PubMed  Google Scholar 

  24. • Muller KE, Roberts E, Zhao L, Jorns JM. Isolated Atypical Lobular Hyperplasia Diagnosed on Breast Biopsy: Low Upgrade Rate on Subsequent Excision With Long-Term Follow-up. Arch Pathol Lab Med. 2018;142(3):391–5. https://doi.org/10.5858/arpa.2017-0155-OAWith careful radiologic-pathologic correlation, the upgrade rate for isolated atypical lobular hyperplasia on biopsy was 3.4%.

    Article  PubMed  Google Scholar 

  25. Page DL, Vander Zwaag R, Rogers LW, Williams LT, Walker WE, Hartmann WH. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst. 1978;61(4):1055–63.

    CAS  PubMed  Google Scholar 

  26. Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007;25(19):2671–7.

    Article  PubMed  Google Scholar 

  27. •• Bevers TB, Helvie M, Bonaccio E, et al. Breast Cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(11):1362–89. https://doi.org/10.6004/jnccn.2018.0083Current guidelines for the management of lobular neoplasia.

    Article  Google Scholar 

  28. • Speer ME, Huang ML, Dogan BE, et al. High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018;91(1090):20180300. https://doi.org/10.1259/bjr.20180300Patients with imaging-concordant MRI-VAB diagnsosi of AHD or LCIS have a low upgrade rate.

    Article  PubMed  PubMed Central  Google Scholar 

  29. • Falomo E, Adejumo C, Carson KA, Harvey S, Mullen L, Myers K. Variability in the Management Recommendations Given for High-risk Breast Lesions Detected on Image-guided Core Needle Biopsy at U.S. Academic Institutions. Curr Probl Diagn Radiol. 2019;48(5):462–6. https://doi.org/10.1067/j.cpradiol.2018.06.004Breast imagers at U.S. academic institutions recommended LCIS for excision 71% of the time and ALH 61% of the time.

    Article  PubMed  Google Scholar 

  30. Anderson JA. Multicentric and bilateral appearance of lobular carcinoma in situ of the breast. Acta Pathol Microbiol Scand A. 1974;82(6):730–4.

    CAS  PubMed  Google Scholar 

  31. Farrow JH. Current concepts in the detection and treatment of the earliest of the early breast cancers. Cancer. 1970;25(2):468–77. https://doi.org/10.1002/1097-0142(197002)25:2<468::aid-cncr2820250226>3.0.co;2-0.

    Article  CAS  PubMed  Google Scholar 

  32. Urban JA. Biopsy of the “normal” breast in treating breast cancer. Surg Clin North Am. 1969;49(2):291–301. https://doi.org/10.1016/s0039-6109(16)38788-6.

    Article  CAS  PubMed  Google Scholar 

  33. • Nakhlis F, Gilmore L, Gelman R, et al. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol. 2016;23(3):722–8. https://doi.org/10.1245/s10434-015-4922-4In this prospective study of 77 patients with pure LN on CB, the upgrade rate was 3% by local pathology and 1% by central pathology review, demonstrating that routine excision is not indicated for patients with pure LN on CB and concordant imaging findings.

    Article  PubMed  Google Scholar 

  34. Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E. Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer. 2013;119(5):1073–9. https://doi.org/10.1002/cncr.27841.

    Article  PubMed  Google Scholar 

  35. Atkins KA, Cohen MA, Nicholson B, Rao S. Atypical lobular hyperplasia and lobular carcinoma in situ at core breast biopsy: use of careful radiologic-pathologic correlation to recommend excision or observation. Radiology. 2013;269(2):340–7. https://doi.org/10.1148/radiol.13121730.

    Article  PubMed  Google Scholar 

  36. Shah-Khan M, Geiger XJ, Reynolds C, Jakub JW, Deperi ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19(10):3131–8. https://doi.org/10.1245/s10434-012-2534-9.

    Article  PubMed  Google Scholar 

  37. • Wong SM, King T, Boileau J-F, Barry WT, Golshan M. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol. 2017;24(9):2509–17. https://doi.org/10.1245/s10434-017-5867-6Women with a LCIS diagnosis had a 10- and 20-year cumulative incidence of subsequent breast malignancy of 11.3% and 19.8% respecivetly. The 10- and 20-year BCSS for women with LCIS was 98.9 and 96.3%, respectively.

    Article  PubMed  Google Scholar 

  38. King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating Clinicopathologic features and breast Cancer risk. J Clin Oncol. 2015;33(33):3945–52. https://doi.org/10.1200/JCO.2015.61.4743.

    Article  PubMed  PubMed Central  Google Scholar 

  39. • Schmidt H, Arditi B, Wooster M, et al. Observation versus excision of lobular neoplasia on core needle biopsy of the breast. Breast Cancer Res Treat. 2018;168(3):649–54. https://doi.org/10.1007/s10549-017-4629-2Cases of LN alone diagnosed on CNB with concorrdant imaging had an upgrade rate of 4%. The upgrade was higher if discordant imaging was found.

    Article  PubMed  Google Scholar 

  40. Ciocca RM, Li T, Freedman GM, Morrow M. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol. 2008;15(8):2263–71. https://doi.org/10.1245/s10434-008-9960-8.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):553–64. https://doi.org/10.1016/j.ijrobp.2013.11.012.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Khoury T, Karabakhtsian RG, Mattson D, Yan L, Syriac S, Habib F, et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology. 2014;64(7):981–93. https://doi.org/10.1111/his.12353.

    Article  PubMed  PubMed Central  Google Scholar 

  43. • Nakhlis F, Harrison BT, Giess CS, et al. Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Ann Surg Oncol. 2019;26(1):55–61. https://doi.org/10.1245/s10434-018-6937-076 patients were diagnosed with NC-LCIS on core biopsy followed by excision, and 36% of cases were upgraded, supporting routine excision.

    Article  PubMed  Google Scholar 

  44. Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol. 2015;22(13):4263–9. https://doi.org/10.1245/s10434-015-4552-x.

    Article  PubMed  PubMed Central  Google Scholar 

  45. • Guo T, Wang Y, Shapiro N, Fineberg S. Pleomorphic Lobular Carcinoma in Situ Diagnosed by Breast Core Biopsy: Clinicopathologic Features and Correlation With Subsequent Excision. Clin Breast Cancer. 2018;18(4):e449–54. https://doi.org/10.1016/j.clbc.2017.10.004The upgrade rate for PLCIS without microinvasion diagnosed by BCBx was 60%.

    Article  PubMed  Google Scholar 

  46. • Foschini MP, Miglio R, Fiore R, et al. Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature. Eur J Surg Oncol. 2019;45(12):2279–86. https://doi.org/10.1016/j.ejso.2019.07.11The data presented here indicate that P/F LCIS is frequently associated with invasive carcinoma or high grade DCIS and that pre-operative biopsy is associated with an underestimation of malignancy. Open surgery is indicated when P/F LCIS is diagnosed pre-operatively.

    Article  PubMed  Google Scholar 

  47. • Fasola CE, Chen JJ, Jensen KC, Allison KH, Horst KC. Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. Breast J. 2018;24(1):66–9. https://doi.org/10.1111/tbj.12843Among all cases of PLCIS, 47 (60%) were associated with invasive carcinoma and/or ductal carcinoma in situ (DCIS) after final surgical excision. Of the 20 cases with PLCIS alone on core needle biopsy (CNB), 6 (30%) were upgraded to invasive carcinoma or DCIS after final surgical excision.

    Article  PubMed  Google Scholar 

  48. • Hoffman DI, Zhang PJ, Tchou J. Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution’s experience. Surg Oncol. 2019;28:190–4. https://doi.org/10.1016/j.suronc.2019.01.009Patients diagnsoed with pure NC-LCIS on biopsy underwent breast conservation surgery 80.8% of the time, while 19.2% underwent mastectomy. At the time of definitive surgery, 11.5% were upstaged. No recurrences in patients with negative margins were observed. One patient with positive margins developed a recurrence 8.3 years post-surgery, and one patient with close margins did 2.2 years post-surgery.

    Article  PubMed  Google Scholar 

  49. Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med. 2011;135(6):737–43. https://doi.org/10.1043/2010-0204-OA.1.

    Article  PubMed  Google Scholar 

  50. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62. https://doi.org/10.1093/jnci/dji372.

    Article  CAS  PubMed  Google Scholar 

  51. Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75. https://doi.org/10.1016/S1470-2045(14)71171-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41. https://doi.org/10.1001/jama.295.23.joc60074.

    Article  CAS  PubMed  Google Scholar 

  53. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91. https://doi.org/10.1056/NEJMoa1103507.

    Article  CAS  PubMed  Google Scholar 

  54. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (London, England). 2014;383(9922):1041–8. https://doi.org/10.1016/S0140-6736(13)62292-8.

    Article  CAS  Google Scholar 

  55. • Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD. Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ. Cancer Prev Res (Phila). 2017;10(8):434–41. https://doi.org/10.1158/1940-6207.CAPR-17-0100Uptake is estimated to be less than 15%. Compared with women with atypical hyperplasia, LCIS and DCIS were significantly associated with chemoprevention uptake, as was medical oncology referral. Younger women were less likely to take chemoprevention.

    Article  CAS  Google Scholar 

  56. Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemoprevention. A suggested approach from the U.S. preventive services task force. Am J Prev Med. 2004;26(1):56–66.

    Article  PubMed  Google Scholar 

  57. •• Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast Cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(33):3152–65. https://doi.org/10.1200/JCO.19.01472Current guidelines for the use of chemoprevention in women with high risk lesions.

    Article  PubMed  Google Scholar 

  58. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89. https://doi.org/10.3322/canjclin.57.2.75.

    Article  PubMed  Google Scholar 

  59. King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, et al. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat. 2013;142(2):445–53. https://doi.org/10.1007/s10549-013-2725-5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

    Ashley M. DiPasquale

  2. Department of Surgery, University of Alberta, Edmonton, AB, Canada

    Ashley M. DiPasquale

  3. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA

    Faina Nakhlis

  4. Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA

    Faina Nakhlis

Authors
  1. Ashley M. DiPasquale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faina Nakhlis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faina Nakhlis.

Ethics declarations

Conflict of Interest

Ashley DiPasquale and Faina Nakhlis declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Non-Invasive Breast Cancer Diagnosis and Treatment

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DiPasquale, A.M., Nakhlis, F. Lobular Neoplasia. Curr Breast Cancer Rep 12, 36–43 (2020). https://doi.org/10.1007/s12609-020-00353-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-020-00353-4

Keywords

Search

Navigation